MedTrace Logo

Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study

NCT02844270 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-11-21

No results posted yet for this study

Summary

The Galaxy First-in-man study is a small pilot. single arm research , which will enroll a total of 45 patients. The goal is to access the feasibility, safety and efficacy of Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in the treatment of patients with de novo coronary lesion.

Conditions

  • Heart Diseases

Interventions

DEVICE

Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Sponsors & Collaborators

  • Shanghai Bio-heart Biological Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-09
Primary Completion
2016-12-22
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844270 on ClinicalTrials.gov